Alnylam Pharmaceuticals Initiates Second Phase I Clinical Study Of ALN-RSV01, An RNAi Therapeutic For The Treatment Of Respiratory Syncytial Virus (RSV) Infection

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 19, 2005--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase I study in the U.S. to evaluate the human safety and pharmacology of ALN-RSV01, an RNAi therapeutic, in healthy volunteers. Earlier this month, Alnylam initiated its first Phase I study in Europe and reported the clearance of its investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA).